Captor Therapeutics (CTX) Q4 2024 earnings summary

Executive summary

• Four independent drug development projects, each with potential for IND/CTA filings annually over the next three years, targeting major diseases such as hepatocellular carcinoma and various cancers.

• All candidates are first-in-class, aiming to maximize commercialization and deal value, with low operating costs providing a competitive edge.

• Key value inflection points expected for CT-01 and CT-03 as they progress through Phase I clinical trials.

Financial highlights

• Research and development income for 2024 was 15,825, with subsidy (grant) revenues of 5,842.

• Gross profit on sales reached 10,595, but significant R&D (43,900) and administrative expenses (11,455) led to an operating loss of -38,967.

• Net loss for the period was -38,426.

Outlook and guidance

• CT-01 Phase I clinical trial in hepatocellular carcinoma is starting, with interim results expected around the turn of 2025/2026.

• CT-03 GLP-tox study and completion of the Investigator's Brochure are planned for the second half of 2025.